Details of the Drug

General Information of Drug (ID: DMP3CSV)

Drug Name

AZD4604

Synonyms

JAK1-IN-7; AZD4604; 2241039-81-4; AZD-4604; JAC34RRR7S; (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; londamocitinib; UNII-JAC34RRR7S; CHEMBL4447181; SCHEMBL20399395; GTPL11716; BDBM488779; EX-A5343; US10961228, Example 35; AKOS040733485; AT39356; example 35 [WO2018134213A1]; MS-30607; HY-126294; CS-0101485; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C28H31F2N7O4S
Canonical SMILES: CN1CCN(CC1)C(COC)C(=O)NC2=CC=CC3=C2NC=C3C4=NC(=NC=C4F)NC5=C(C(=CC=C5)S(=O)(=O)C)F
InChI: InChI=1S/C28H31F2N7O4S/c1-36-10-12-37(13-11-36)22(16-41-2)27(38)33-21-8-4-6-17-18(14-31-26(17)21)25-19(29)15-32-28(35-25)34-20-7-5-9-23(24(20)30)42(3,39)40/h4-9,14-15,22,31H,10-13,16H2,1-3H3,(H,33,38)(H,32,34,35)/t22-/m1/s1
InChIKey: JNUZADQZHYFJGW-JOCHJYFZSA-N

Cross-matching ID

PubChem CID: 135240395
TTD ID: DX72LV

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Inhibitor	[2]
Janus kinase 2 (JAK-2)	TTRMX3V	JAK2_HUMAN	Inhibitor	[2]
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04769869) A Single-blind, Randomized, Placebo-controlled 3 Part Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 Following Single and Multiple Ascending Doses and to Investigate the Anti-inflammatory Effect of Inhaled AZD4604. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of AstraZeneca